– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA –

– PDUFA Target Action Date of November 22, 2026 –

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Company’s lead asset for the treatment of Duchenne muscular dystrophy (DMD), will be presented in a late-breaking poster and an oral presentation at the 31st Annual Congress of the World Muscle Society (WMS 2026), taking place September 29 – October 3, 2026, in Hiroshima, Japan. The presentations will report skeletal muscle and cardiac outcomes through 24 months, building on the previously reported 12-month HOPE-3 results. Of the 106 patients randomized in HOPE-3, 82 reached the 24-month time point, comprising 40 originally assigned to Deramiocel and 42 to placebo.

“These HOPE-3 24-month data, along with additional analyses supporting Deramiocel’s potential safety and efficacy, were part of our recent major amendment to the Deramiocel BLA,” said Linda Marbán, Ph.D., CEO of Capricor. “We look forward to presenting these results at the World Muscle Society Congress.”

Beyond the Deramiocel program, Capricor will also present two preclinical posters from its StealthX™ exosome platform.

WMS Presentations

Title: Deramiocel slows upper limb decline in the HOPE-3 OLE: cross-phase delayed-start analysis and 2-year comparison with natural history
Presenting author: Dr. Craig McDonald, University of California, Davis
Details: Late-breaking poster session

Title: HOPE-3, a phase 3 study of deramiocel, an allogeneic cell therapy, in advanced Duchenne muscular dystrophy: evidence to support both musculoskeletal and cardiac efficacy
Presenting author: Dr. Craig McDonald
Details: Oral presentation, clinical trial updates session, October 3, 2026

Title: Engineered muscle-targeting extracellular vesicles for systemic delivery of micro-dystrophin: novel redosable strategy for Duchenne muscular dystrophy
Presenting author: Mafalda Cacciottolo, Ph.D., Capricor Therapeutics
Details: Poster session 2, DMD treatments, September 30, 2026

Title: Delivery of acid α-glucosidase by muscle-targeting extracellular vesicles: a new road for Pompe disease treatment
Presenting author: Mafalda Cacciottolo, Ph.D.
Details: Poster session 3, Glycogenoses, October 2, 2026

Copies of the presentations and posters will be added to the publications section of the Capricor website following each presentation. The full WMS 2026 program is available at https://www.wms2026.com/page/programme.

About the HOPE-3 Study

HOPE-3 is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating Deramiocel in patients with Duchenne muscular dystrophy. The study enrolled 106 patients, randomized to receive Deramiocel or placebo administered intravenously every three months over a 12-month treatment period. HOPE-3 met its primary endpoint, with Deramiocel slowing decline in upper limb function by 54 percent versus placebo as measured by Performance of the Upper Limb (PUL) version 2.0 (p=0.03). One-year results were published in The Lancet in July 2026. Patients who completed the randomized portion of the study were eligible to continue receiving Deramiocel in an open-label extension.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, the leading cause of death in DMD. There is no cure, and treatment options remain limited.

About Deramiocel

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert immunomodulatory and anti-fibrotic actions in the preservation of skeletal and cardiac muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. For the treatment of DMD, Deramiocel holds Orphan Drug, RMAT and Rare Pediatric Disease designations in the U.S., and Orphan Drug and ATMP designations in Europe. The Rare Pediatric Disease designation may qualify Capricor for a Priority Review Voucher upon approval.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval, revenue and reimbursement estimates, projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the Securities and Exchange Commission on August 14, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

Agreement Reserves Approximately $53 Million of Pendergrass Manufacturing Capacity for Northern Ontario Edge AI Data Center Projects

Represents First Commercial Capacity Reservation Under Previously Announced Approximately $200 Million Utility-Scale Framework

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV) (“NeoVolta” or the “Company”), a U.S.-based energy technology company delivering scalable energy storage solutions, today announced that its majority-owned subsidiary, NeoVolta Power, LLC (“NeoVolta Power”), has entered into a binding capacity reservation agreement with Infinite Grid Capital (“IGC”) to provide battery energy storage system (“BESS”) equipment for North Ontario Edge artificial intelligence datacenter (“Edge AIDC”) projects for calendar year 2027.

Today’s announcement represents the first major commercial commitment under NeoVolta Power’s previously announced utility-scale framework with IGC, which contemplates approximately 1.1 GWh of potential BESS deployments and approximately $200 million of potential supply across multiple markets. The approximately $53M binding commitment advances the Company’s strategy of converting early utility-scale demand visibility into binding commercial relationships as its Pendergrass manufacturing platform progresses through commissioning and production-ramp activities.

“This is an important commercial milestone for NeoVolta Power and a meaningful validation of the platform we have built at Pendergrass,” said Ardes Johnson, Chief Executive Officer of NeoVolta. “The project demonstrates how our BESS manufacturing, a differentiated supply-chain strategy, and scalable energy-storage products can address the rapidly growing power-infrastructure needs of data centers and other energy-intensive customers. As we advance the production ramp at Pendergrass, our focus is on executing this initial commitment and converting additional qualified demand into binding customer orders.”

Utility-Scale Demand Validation

The capacity reservation agreement is intended to support the Northern Ontario Edge AIDC project and represents an initial commercial step within NeoVolta’s broader relationship with IGC. The relationship was previously announced as a non-binding framework spanning approximately 1.1 GWh of potential demand.

The Company believes the initial data-center-related commitment is strategically significant. Growth in artificial intelligence and data-center infrastructure is increasing the need for reliable, scalable power solutions, and BESS is expected to play an increasingly important role in supporting grid reliability, load management, and project-level energy resilience. The commitment provides commercial validation for NeoVolta Power’s utility-scale product offering and its domestic BESS manufacturing strategy.

Pendergrass Grand Opening

NeoVolta will host a grand-opening ceremony for its NeoVolta Power facility in Pendergrass, Georgia, later today. Members of NeoVolta management, key strategic partners, media, and local officials are expected to attend.

The event marks the official opening of the Company’s 210,600-square-foot facility, a purpose-built domestic BESS manufacturing platform designed to assemble commercial, industrial, and utility-scale energy-storage products. The Company’s initial Pendergrass production line is advancing through commissioning and Site Acceptance Testing, and the production ramp remains on track for the fourth quarter of calendar 2026.

NeoVolta expects to provide additional updates regarding the commissioning process, manufacturing milestones, and commercial activity as appropriate.

About Infinite Grid Capital

Infinite Grid Capital (“IGC”) is an energy infrastructure investment platform that develops and finances large-scale power projects, including battery energy storage systems, hybrid energy hubs, and dedicated power solutions for data centers across North America and selected global markets, including key U.S. power regions such as California, Texas, and the Southeastern United States. IGC focuses on building reliable and flexible energy assets that ensure continuous power for AI workloads, industrial operations, and other mission-critical facilities. Infinite Grid Capital is an existing strategic investor in NeoVolta and provides offtake origination and related advisory services in connection with NeoVolta Power’s BESS manufacturing operations.

For more information, visit www.infinitegridcapital.com.

About NeoVolta

NeoVolta is an innovator in energy storage solutions dedicated to advancing reliable, high-performance power infrastructure for residential, commercial, and utility applications. With a focus on scalable technology, domestic manufacturing, and strategic partnerships, NeoVolta is positioned to support the accelerating transition toward resilient energy systems.

For more information, visit www.neovolta.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include statements regarding the Company’s business strategy, plans, objectives, expectations, and future operations; the anticipated timing and benefits of the Company’s manufacturing activities; the Company’s ability to execute its production ramp and achieve manufacturing and commercial milestones; anticipated customer demand, project opportunities, and order conversion; and the Company’s growth plans and future financial and operating performance.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, risks related to market conditions; customer demand; the Company’s ability to execute its business strategy and manufacturing plans; supply-chain availability and costs; project development, permitting, construction, and deployment activities; the availability of financing; changes in laws, regulations, tax incentives, tariffs, or trade policies; competition; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

NEOV Investors
Bryan Baritot
Alliance Advisors IR
ir@neovolta.com  

NEOV Media
Email: press@neovolta.com
Phone: 800-364-5464

  • Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome
  • Top-line results remain on track for late November 2026

NESS ZIONA, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced that the last patient has completed the last scheduled study visit in the Company’s pivotal Phase 3 clinical trial (SGT-610-01) evaluating SGT-610 (patidegib gel, 2%) for the prevention of BCC (basal cell carcinoma) lesions in adult patients with Gorlin syndrome.

The achievement of last patient last visit (LPLV) marks the completion of the patient treatment and follow-up phase of the study. The Company is now proceeding with database lock, followed by statistical analysis of the study results. Sol-Gel expects to report top-line results in late November 2026. The Company, investigators and patients remain blinded to treatment assignment.

The randomized, double-blind, vehicle-controlled Phase 3 study enrolled 113 patients with Gorlin syndrome, of whom 102 completed the study. Patients were randomized to receive SGT-610 or vehicle for 12 months of treatment. The primary endpoint of the study is the number of new BCCs on the face at month 12 after twice daily treatment. Secondary endpoints include the number of new surgically eligible BCCs (SEBCCs).

Mr. Mori Arkin, Executive Chairman and CEO of Sol-Gel, stated: “Reaching last patient last visit represents an important milestone for the SGT-610 program and brings us closer to understanding its potential to address the significant unmet need in patients with Gorlin syndrome. We are grateful to the patients, investigators and clinical site teams whose participation and commitment made this study possible. We look forward to completing the analysis and reporting the results.”

About Sol-Gel Technologies

Sol-Gel is a specialized dermatology company advancing innovative therapies for rare and serious skin diseases. Its lead investigational candidate, SGT-610 (patidegib gel, 2%), is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome, with the potential to offer an improved safety profile relative to oral hedgehog inhibitors. Subject to regulatory approval in Gorlin syndrome, SGT-610 may also represent a future opportunity in high-frequency BCC. Sol-Gel is also advancing SGT-210, an investigational topical EGFR inhibitor for indications with significant unmet need, and has developed two FDA-approved dermatology products, TWYNEO® and EPSOLAY®.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. including, but not limited to statements regarding the timing of the release of top-line results for the Phase 3 program of SGT-610 in Gorlin syndrome. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management’s current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, the risk of a delay in reporting the top-line results of Sol-Gel’s pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, that we will not successfully complete the Gorlin Phase 3 clinical trial or that such clinical trial will fail to meet its primary endpoint or one or more of its secondary endpoints as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaborators’ ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaborators’ ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators’ ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, China, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and, (xvii) the security situation in Israel. These factors and other important factors discussed in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 19, 2026, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this press release.

Sol-Gel Investor Relations:
Eyal Ben-Or
Chief Financial Officer
ir@sol-gel.com

TOKYO, Sept. 17, 2026 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd (Nasdaq: LRE) (“LRE” or “the Company”), a Japanese real estate developer, today announced the opening of reservations for JINRYU HOTEL IZUMO, a new luxury Japanese-style all-suite hotel designed for extended stays near Izumo Taisha, one of Japan’s most historic landmarks. Reservations opened on September 1, 2026.

Located at 597-2 Shurimen, Taisha-cho, Izumo-shi, Shimane, the four-story property features six large suites, each accommodating six or more guests. The top-floor living room offers a direct view of Izumo Taisha’s grand torii gate.

“We created JINRYU HOTEL IZUMO to offer guests a quiet, restorative place to stay in one of Japan’s most historic regions. Our focus was on spacious design and a calm environment that supports extended stays.” — Eiji Nagahara, Representative Director, President, and Chief Executive Officer, Lead Real Estate Co., Ltd.

The JINRYU HOTEL series was developed through a collaboration between Lead Real Estate and Ryuka First-Class Architect Office, led respectively by President Eiji Nagahara and architect Hiroshi Fuwa. Each suite provides over 60 square meters of space, with complimentary on-site parking available for guests with advance reservations.

Lead Real Estate Co., Ltd

The exterior of JINRYU HOTEL IZUMO (Source: Lead Real Estate)

Lead Real Estate Co., Ltd

Suite interior at JINRYU HOTEL IZUMO (Source: Lead Real Estate)

About Lead Real Estate Co., Ltd.

Lead Real Estate Co., Ltd is a Japanese developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The Company also operates hotels in Tokyo and leases apartment units in Japan and Dallas, Texas. For more information, visit https://www.lead-real.co.jp/en/.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and other factors that may affect future results, as described in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information

Ken Takahashi
Chief Financial Officer
Lead Real Estate Co., Ltd.
Email: k-takahashi@lead-real.co.jp
Tel: +81 3-5784-5127

AUM Advisors
Crocker Coulson
Email: crocker.coulson@aumadvisors.com
Tel: +1 (646) 652-7185

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/a4134598-9881-41f2-9657-467160da6e99

https://www.globenewswire.com/NewsRoom/AttachmentNg/a2154830-d48e-4f96-8d17-9b6fa9bab33b

  • Standardized SIS Selling Packages Accelerate Closings and Retrofits, with Recent Purchase Orders slated for Q3-Q4 revenue recognition. 
  • SteraBox aimed at recycling, electronics refurbishment, and circular-economy use.

FREDERICK, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions today reported accelerating traction in its SteraMist iHP enclosure product line, with roughly $2.3 million in purchase orders year-to-date. That figure already exceeds by 44% the $1.6 million in comparable enclosure orders generated over the previous four years combined — highlighting rapidly expanding customer adoption and a powerful growth engine in SteraMist iHP technology tied to enclosure use.

This order activity follows the Company’s 2024/2025 focus on its SteraMist Integration System (“SIS”) platform of products; a more standardized product grouping built to close faster, deliver faster, and fit the way customers already operate. While enclosure projects were largely custom in prior years, the enhanced SIS platform now reduces that custom requirement, offering configured answers with only minimal customization and enabling iHP to be retrofitted into customer installed equipment easier.

This shift is visible in two of the Company’s most recent purchase orders received within the past week. A portion of both orders is expected to be recognized as revenue this quarter upon delivery, with related services recognized next quarter. Both are retrofits of SteraMist iHP into customers’ existing enclosures. In each case, iHP will replace the customer’s prior decontamination process and integrate directly into their current enclosure, giving the customer a path to validated iHP decontamination without a full equipment replacement. One customer displaced chlorine dioxide; the other transitioned its current decontamination method to SteraMist iHP. With both customers utilizing the SIS platform rather than a lengthy custom build, both orders are positioned for nearer-term delivery and revenue recognition in the second half of 2026.

Demand is concentrated in enclosed, controlled environments used throughout life sciences research, manufacturing, and quality operations. These include biosafety cabinets (BSCs); restricted access barrier systems (RABS); isolators and gloveboxes; pass-through chambers and material airlocks; aseptic filling and packaging-line enclosures; sterility-test, compounding, and cell-and-gene-therapy chambers; lyophilizer and freeze-dryer isolators; and other barrier systems in which surfaces and air must be decontaminated to a validated standard without damaging sensitive materials or instruments.

These orders exclude the Company’s active pipeline of automated custom-design work; Custom Engineered Systems currently retains an active pipeline totaling $3.2 million.

“Last year’s development of our SIS strategy is playing out well, and we expect additional enclosure projects to close,” said Elissa J. (E.J.) Shane, Chief Operating Officer of TOMI. “We can now move from interest to purchase order, and from purchase order to delivery, on a timeline that prior custom work could not support. The flexibility we have built—not only in the technology, but in our selling packages—is key. Customers can adopt iHP as a retrofit of equipment they already own or as a standardized chamber, and that range of options is converting demand we could not always capture before.”

In parallel, TOMI continues to work with one domestic partner and one international partner on a standardized, all-encompassing iHP chamber—an upgraded SteraBox—intended as a cost-effective offering for additional markets. The design draws down the performance bar already required in life sciences and packages it for commercial and daily-use customers who need routine, high-level sanitization outside traditional pharmaceutical and laboratory settings. Target applications include recycling and circular-economy workflows; electronics, medical device and laboratory equipment refurbishment; returned consumer and industrial goods before resale; and other sustainability-driven operations in which shared, reused, or reclaimed items must be decontaminated before they re-enter commerce.

Those use cases rest on the same performance profile that has driven life sciences adoption. SteraMist iHP, a DARPA-originated technology, combines high efficacy with broad material compatibility. That combination is making iHP an increasingly common choice for sensitive equipment—not only in aseptic processing, but anywhere operators want sterilization that is effective on the target and compatible with the asset being treated.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements related to expected revenue recognition of SteraMist iHP products. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:  

John Nesbett/Zach Nevas

IMS Investor Relations  

tomi@imsinvestorrelations.com  

Federal security orders, first project awards under newly acquired PES engineering business, and major Valerus platform release highlight recent momentum across Security and Industrial segments

Hauppauge, NY, Sept. 17, 2026 (GLOBE NEWSWIRE) — Cemtrex, Inc. (Nasdaq: CETX, CETXP), a diversified industrial and technology company, today announced that its Vicon Industries subsidiary has received orders totaling approximately $2.8 million in the current fiscal quarter from a U.S. federal government agency, through an existing channel partner, for its video surveillance products and Valerus video management platform. The orders are expected to ship in the current fiscal quarter.

The awards reflect continued expansion of Vicon’s business with federal government customers, following the approximately $2 million correctional facility order in the United Kingdom announced in May 2026, and underscore sustained institutional and public-sector demand for the Valerus platform.

Separately, Vicon released Valerus 26.1, a major update to its video management software. The release introduces GPU-accelerated video processing, delivering smoother, faster streaming and forward and reverse playback at speeds up to 1000x directly in the browser. The upgrade represents a significant advancement for the web client and a direct investment in Vicon’s core markets of government, corrections, and education, where customers have operated Vicon systems for decades.

In the Company’s Industrial Services segment, Plant Engineering Services (PES), the engineering business Cemtrex acquired on July 1, 2026, has been awarded five projects totaling approximately $410,000 in support of a 5,000-ton water press restoration and modernization program for a leading precision forging manufacturer in California. The awarded scope spans engineering, equipment design, fabrication, assembly, installation, and system integration, including a turnkey accumulator level control system, control panel upgrades, and hydraulic system modernization.

“Federal orders of this scale demonstrate that the work at Vicon is converting into results,” said Saagar Govil, Chairman and CEO of Cemtrex. “Government, corrections, and education are demanding environments where reliability wins, and the combination of these orders and the Valerus 26.1 release shows the platform earning that confidence.”

“PES is generating meaningful project awards within its first full quarter as part of Cemtrex,” Govil added. “That is the acquisition model working as intended: acquiring durable businesses and supporting them as they grow. We remain focused on disciplined execution across all of our segments.”

About Cemtrex
Cemtrex, Inc. (Nasdaq: CETX) is a diversified industrial and technology company operating across the Security, Industrial, and Aerospace & Defense sectors. The Company’s Security segment, led by Vicon Industries, provides advanced video management software, high-performance security cameras, and integrated surveillance solutions for enterprise, government, and critical infrastructure customers. Its Industrial segment, through Advanced Industrial Services (AIS), delivers specialized rigging, millwrighting, process piping, and equipment installation services to manufacturers nationwide. Cemtrex’s Aerospace & Defense segment, anchored by Invocon, provides mission-critical engineering, instrumentation, and sensing solutions supporting aerospace, defense, and space-based programs. With a focus on disciplined execution and strategic growth, Cemtrex is committed to building durable businesses that enhance safety, reliability, and long-term value for its customers and shareholders.
For more information, visit www.cemtrex.com.

Investor Relations: investors@cemtrex.com

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating tovthe expected contribution of the acquired business, future sales, or any future potential acquisition. These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.

CONTACT: investors@cemtrex.com

Closing Bell ceremony celebrating Pasqal’s recent public listing and marking its next chapter as a publicly traded company

PARIS and NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Pasqal (NASDAQ: PSQL), a global leader in neutral-atom quantum computing, today announced that it will ring the Nasdaq Closing Bell on September 17, 2026, marking the company’s recent public listing under the ticker symbol PSQL.

The ceremony marks an important milestone in Pasqal’s journey, from pioneering quantum computing research to developing and deploying quantum solutions that address real-world challenges today. Pasqal is working with businesses, research institutions and public authorities around the world to explore and deliver practical applications of quantum computing across industries.

As a public company, Pasqal intends to accelerate the global deployment of its quantum computing platform, support continued innovation, and expand the adoption of quantum computing in commercial and public-sector applications worldwide. The company’s focus remains firmly on translating advances in quantum technology into solutions that can address complex problems beyond the reach of today’s most powerful classical computers.

“Ringing the Nasdaq Closing Bell is a proud moment for us and for everyone, from our employees and founders to our investors, who has contributed to building the company we are today,” said Wasiq Bokhari, Chief Executive Officer of Pasqal. “Pasqal was founded on the belief that the neutral-atom approach to quantum computing could deliver high-value solutions to real-world, complex challenges. Today, we are seeing that belief translate into concrete opportunities for businesses, researchers, and public-sector organizations. This milestone reflects how far we have come, but more importantly, it opens a new chapter for what we’re building next. We look forward to continuing to advance our technology, expand our international presence, and work alongside our customers and partners to deliver the benefits of quantum computing today.”

The Nasdaq Closing Bell ceremony will take place on September 17, 2026 at 4 p.m. ET at the Nasdaq MarketSite in Times Square, New York City. The ceremony will be livestreamed on Nasdaq’s official channels and can be viewed at: Bell Ringing Ceremony.

Contacts

Investors
investors@pasqal.com

Media
pr@pasqal.com

About Pasqal
Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future.

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network).

Forward-Looking Statements
Certain statements herein may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “might”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “could,” “plan,” “predict,” “project”, “forecast,” “potential,” “seem,” “seek,” “target,” “possible,” “future,” “outlook” or similar terminology or expressions that predict or indicate future events or trends. These forward-looking statements include, but are not limited to, statements regarding future events, including Pasqal’s ability to accelerate global deployment of its quantum computing platform.

These statements are based on current expectations and are not predictions of actual performance. They are provided for illustrative purposes only and must not be relied on as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and are beyond the control of Pasqal. These statements are subject to known and unknown risks and uncertainties and assumptions regarding Pasqal’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political, social and business conditions; uncertainty or changes with respect to laws and regulations; risks related to Pasqal’s indebtedness; the risk from Pasqal pursuing an emerging technology, facing significant technical challenges and the potential that it may not achieve commercialization or market acceptance; Pasqal’s reliance on strategic partners and other third parties; Pasqal’s ability to maintain, protect and defend its intellectual property rights; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the “SEC”). The foregoing list of risk factors is not exhaustive. There may be additional risks that Pasqal does not know or currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Pasqal’s expectations, plans and forecasts of future events and views as of the date of this communication. While Pasqal may elect to update these forward-looking statements in the future, Pasqal specifically disclaims any obligation to do so.

Seasoned Finance Executive with Extensive Experience Across Nasdaq-Listed Companies and Institutional Firms to Support Duke’s Growth Strategy

Strengthens Executive Leadership Team to Accelerate Growth Plans as Company Seeks to Scale Innovative Drone Platforms Across Defense and Civilian Markets

FT. LAUDERDALE, FL, Sept. 17, 2026 (GLOBE NEWSWIRE) — Duke Robotics Corp. (Nasdaq: DUKR; DUKRW) (“Duke Robotics” or the “Company”), a leader in advanced robotics and drone-based solutions for civilian and defense markets, today announced the appointment of Avi Levin as Chief Financial Officer, effective October 1, 2026. Mr. Levin succeeds Shlomo Zakai, who is expected to continue providing financial and corporate consulting services to the Company to support a seamless transition of financial operations.

The appointment comes as Duke Robotics enters an accelerated growth phase following its recent Nasdaq uplisting and the arrival of Chief Executive Officer Yiftach Kleinman. As the Company looks to scale commercial adoption of its drone platforms across defense and civilian markets, and expand its offerings, the Company believes Mr. Levin will play a key role in developing Duke’s financial strategy, capital allocation, and corporate initiatives to support its growing operational footprint and strategic expansion plans.

“Since assuming the role of Chief Executive Officer, my focus has been to accelerate our operational tempo and assemble the executive leadership required to execute our growth strategy,” said Yiftach Kleinman, Chief Executive Officer of Duke Robotics. “Duke is at a pivotal inflection point. In the civilian sector, our utility grid solutions are commercially validated and addressing an urgent need for power infrastructure resilience amid rising geopolitical challenges and surging energy demand associated with, among other things, artificial intelligence. In defense, our battle-tested platforms are advancing toward broader commercialization. Bringing on an executive of Avi’s caliber is central to pursuing this market opportunity. He brings a rare combination of deep capital markets experience, proven public company CFO leadership, and strategic transaction expertise that we believe will be instrumental in scaling our business. On behalf of our Board of Directors and the entire Company, I also want to thank Shlomo Zakai for his dedicated financial stewardship through our Nasdaq uplisting, and we look forward to his continued support.”

Mr. Levin is an accomplished financial executive and certified public accountant with more than two decades of corporate finance, capital markets, and institutional leadership experience across the United States and Israel. Throughout his career, he has raised more than $130 million through private placements and public offerings with Nasdaq-listed issuers. He previously served as Chief Financial Officer of Ability Inc. (NASDAQ: ABIL), where he helped lead three Nasdaq offerings, raising an aggregate of $100 million. He also served as Chief Financial Officer of RAD Data Communications, a leading global telecommunications provider with over $150 million in annual revenue, where he managed a 49-person global finance and IT organization across 11 subsidiaries and led the company’s official Nasdaq IPO readiness initiative. Mr. Levin also served as Chief Financial Officer of enterprise AI software provider BlackSwan Technologies, securing a $30 million institutional financing round. Most recently, he served as a senior financial advisor and executive consultant, advising late-stage technology companies on U.S. capital raising, IPO readiness, and strategic transactions.

Earlier in his career, Mr. Levin worked in New York City at Credit Suisse (now part of UBS), where he worked on initial public offerings, follow-on equity offerings, and debt financings for NYSE-listed companies. He previously held corporate finance and controller positions at Broadridge Financial Solutions (NYSE: BR), where his responsibilities included acquisition accounting and post-merger integration, and served as Financial Reporting Manager at Overseas Shipholding Group (now International Seaways, NYSE: INSW). He began his career in the audit practice of PricewaterhouseCoopers (PwC) in its San Jose, California and Tel Aviv offices. Mr. Levin holds a Master of Business Administration (MBA) from the NYU Stern School of Business and a Bachelor of Arts in Economics and Accounting from Ben-Gurion University of the Negev. He is a Certified Public Accountant (CPA) in both the United States and Israel.

“I am thrilled to join Duke Robotics at such an exciting stage in its development,” said Avi Levin, incoming Chief Financial Officer. “Duke has developed innovative, proprietary drone technologies that I believe address clear and urgent operational needs across critical industries. With a strong public company platform on Nasdaq and energized leadership under Yiftach, the Company is positioned to pursue its growth strategy. I look forward to partnering closely with Yiftach, our Board of Directors, and our talented team to strengthen our financial foundation, support our strategic expansion, and drive long-term value for our shareholders.”

About Duke Robotics
Duke Robotics Corp. (Nasdaq: DUKR; DUKRW) develops advanced stabilization and autonomous robotic drone systems for both civilian and defense markets. The Company’s Insulator Cleaning Drone (IC Drone) is a first-of-its-kind, drone-enabled system for cleaning and monitoring high-voltage electric utility insulators. Leveraging Duke’s technologies, the IC Drone provides a safer, more efficient, and cost-effective alternative method. AEROTRACE™ is the Company’s AI-powered aerial monitoring and intelligence platform for infrastructure operators, designed to deliver actionable insights for asset assessment and proactive maintenance. In defense, through a collaboration agreement with Elbit Systems Land Ltd. (“Elbit”), the Bird of Prey weapons drone system is an agile, fully stabilized remote weapon system designed for non-line-of-sight and stand-off engagements, marketed by Elbit under the brand name Bird of Prey (formerly known as TIKAD). For additional Company information, please visit https://dukeroboticsys.com and follow us on Twitter (X) and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements. Words such as “future” and similar expressions, or future or conditional verbs such as “will,” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs, assumptions, and information currently available to us. For example, we are using forward-looking statements when we discuss the leadership transition and its anticipated benefits, the anticipated timing of Mr. Levin’s commencement of employment, the expected ongoing advisory role of Mr. Zakai, the anticipated benefits of Mr. Levin’s financial leadership and transaction background to the Company’s strategy and capital structure, the Company’s ability to accelerate operational execution and pipeline expansion, and the Company’s opportunities across the defense and energy-infrastructure sectors and beyond. Our actual results may differ materially from those expressed or implied due to known or unknown risks and uncertainties. These include, but are not limited to, risks related to the successful integration of new leadership, the successful market adoption of our technologies, the continued development and refinement of our technology, our ability to effectively collaborate with Elbit Systems, fluctuations in foreign currency exchange rates, operational challenges associated with marketing activities in new markets, economic conditions that may affect defense spending and infrastructure investment, geopolitical factors that could impact business operations, regulatory challenges in various regions, and competition from technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and any subsequent filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Company Contact:
Duke Robotics Corp.
invest@dukeroboticsys.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
duke@arxhq.com

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Sthree plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
16/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary
  Interests

Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled: 6,699,267 5.49    
(2)   Cash-settled derivatives:

4,165,313 3.41 10,597 0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        

        TOTAL:

10,864,580 8.91 10,597 0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale

Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
1p ordinary Equity swap Increasing a long position 6,386 2.8937 GBP

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 17/09/2026
Contact name: Graham Keene
Telephone number: +44 20 7144 2259

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

LOWELL, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) — MACOM Technology Solutions Inc. (“MACOM”), a leading supplier of semiconductor products, today announced a front end chipset solution for 3.2T applications, designed to accelerate the development of next generation optical interconnects for AI infrastructure, cloud data centers and high speed networking applications.

The solution is designed to support new optical architectures, delivering up to 3.2T throughput through eight channels operating at 448 Gbps PAM-4. This solution combines MACOM’s new high performance transimpedance amplifiers (TIAs) and photodiodes in a receiver platform with its previously introduced 448 Gbps PAM-4 drivers on the transmit side. By offering key transmit and receive building blocks from a single supplier, MACOM helps customers simplify development, accelerate time-to-market and optimize overall link performance.

“MACOM’s 3.2T chipset solution has been engineered and optimized as a platform, helping customers optimize link performance while reducing development and qualification efforts,” said Stephen G. Daly, President and Chief Executive Officer, MACOM.

Optimized for 448 Gbps PAM-4 Optical Links
MACOM’s receive-side solution combines advanced photodiodes and TIA technologies engineered to work together in demanding 448 Gbps PAM-4 optical applications.

This solution includes MACOM’s MATA-42754 and MATA-41754 quad linear TIAs, designed to support the bandwidth requirements of next-generation optical links. The devices incorporate RSSI functionality for photo alignment and power monitoring, as well as digital control of bandwidth, output amplitude, peaking, gain and loss-of-signal thresholds.

The TIAs are paired with MACOM’s MARP-BP224 backside-illuminated PIN photodiode, optimized for 448 Gbps PAM-4 receiver applications. The photodiode features greater than 100 GHz bandwidth and ultra-low parasitics to maximize performance and signal integrity in high speed optical links. Leveraging a proprietary design for high coupling efficiency, the device is available in multiple layouts to support a variety of optical interface implementations. Together, these components provide a scalable building block approach for transceivers supporting eight channels at 448 Gbps PAM-4 and aggregate data rates reaching 3.2T.

The new receive-side solution complements MACOM’s previously announced MAOM-025408 and MAOM-022404 driver solutions, which support 448 Gbps PAM-4 optical transmit architectures. By combining drivers, photodiodes and TIAs within a single portfolio, MACOM is providing customers with a comprehensive set of technologies for next-generation optical module development.

Availability
All products within the 3.2T chipset solution are readily available. Please visit www.macom.com or contact your local MACOM sales representative for more information. The products will also be on display at MACOM’s Booth 1055 at ECOC2026 from September 21 to 23, 2026 in Málaga, Spain.

About MACOM
MACOM designs and manufactures semiconductor products for telecommunications, industrial and defense and data center applications. Headquartered in Lowell, Massachusetts, MACOM has design centers and sales offices throughout North America, Europe and Asia. MACOM is certified to the ISO9001 international quality standard and ISO14001 environmental management standard. To learn more, visit https://www.macom.com/.

Company Contact:
MACOM Technology Solutions Inc.
Stephen Ferranti
Senior Vice President, Corporate Development and Investor Relations
P: 978-656-2977
E: stephen.ferranti@macom.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.